Mitral Valve Insufficiency Epidemiology Forecast 2025-2034

Mitral valve insufficiency, or mitral regurgitation (MR), is one of the most common types of valvular heart disease, affecting over 175 million people globally and about 5 million people in the United States. Studies show that the prevalence of the condition is rising, owing to the expanding elderly population with longer life expectancies.

Mitral Valve Insufficiency Epidemiology Forecast Report Coverage

The “Mitral Valve Insufficiency Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Mitral Valve Insufficiency. It projects the future incidence and prevalence rates of mitral valve insufficiency across various populations. The study covers age and type as major determinants of the mitral valve insufficiency-affected population. The report highlights patterns in the prevalence of mitral valve insufficiency over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of mitral valve insufficiency in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Mitral Valve Insufficiency: Disease Overview

In mitral valve insufficiency, the mitral valve in the heart does not close properly, which allows the blood to flow backward into the left atrium. This causes inefficient blood flow through the heart. Primary mitral regurgitation occurs due to problems with the mitral valve itself, such as valve degeneration or damage from an infection. On the other hand, secondary mitral regurgitation results from other heart conditions, such as left ventricular dilation or heart failure, which stretch the heart and affect the proper functioning of the mitral valve.

Mitral Valve Insufficiency: Treatment Overview

The treatment for mitral valve insufficiency depends on the severity of the condition, symptoms, and underlying causes. Diuretics help in removing excess fluid from the body, reducing swelling and fluid buildup in the lungs. ACE inhibitors (angiotensin-converting enzyme inhibitors) are prescribed to lower blood pressure and reduce the workload on the heart. In some cases, blood thinners may be recommended to reduce the risk of blood clots, especially in individuals with atrial fibrillation.

Epidemiology

The mitral valve insufficiency epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for mitral valve insufficiency by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for mitral valve insufficiency and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Mitral regurgitation is one of the most prevalent types of valvular heart disease, both globally and in North America, affecting over 175 million people worldwide and approximately 5 million people in the United States.
• It is estimated that acute and chronic mitral regurgitation affects roughly 5 per 10,000 individuals in the United States.
• In asymptomatic chronic severe degenerative mitral regurgitation, mortality can range from 50-73% over five years, with 27-45% for patients having preserved left ventricular function. Additionally, patients with a flail mitral valve leaflet may experience sudden death at a rate of 1-8% per year.
• Studies reveal that rheumatic heart disease is the primary cause of mitral valve insufficiency (mitral regurgitation) in regions other than the Western world.

Country-wise Mitral Valve Insufficiency Epidemiology

The mitral valve insufficiency epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of mitral valve insufficiency varies significantly between countries due to differences in genetic factors, healthcare access, lifestyle, and the prevalence of underlying conditions such as rheumatic fever, coronary artery disease, and hypertension. In the United States, approximately 1 in 10 individuals have a leak in one of their heart valves. Among these cases, the most common type of valve leak is in the mitral valve.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of mitral valve insufficiency based on several factors.
• The Mitral Valve Insufficiency Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of mitral valve insufficiency are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of mitral valve insufficiency epidemiology in the 8 major markets?
• What will be the total number of patients with mitral valve insufficiency across the 8 major markets during the forecast period?
• What was the country-wise prevalence of mitral valve insufficiency in the 8 major markets in the historical period?
• Which country will have the highest number of mitral valve insufficiency patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of mitral valve insufficiency during the forecast period of 2025-2034?
• What are the currently available treatments for mitral valve insufficiency?
• What are the disease risks, signs, symptoms, and unmet needs of mitral valve insufficiency?

This product will be delivered within 3-5 business days.